

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8620747/publications.pdf Version: 2024-02-01



Νι Ελν

#	Article	IF	CITATIONS
1	Δ9-THC-Caused Synaptic and Memory Impairments Are Mediated through COX-2 Signaling. Cell, 2013, 155, 1154-1165.	28.9	166
2	Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for <i>in vivo</i> î"9â€THC exposureâ€impaired hippocampal synaptic plasticity. Journal of Neurochemistry, 2010, 112, 691-702.	3.9	76
3	Altered serum levels of TNF-α, IL-6, and IL-18 in depressive disorder patients. Human Psychopharmacology, 2017, 32, e2588.	1.5	59
4	Altered serum levels of TNF-α, IL-6 and IL-18 in manic, depressive, mixed state of bipolar disorder patients. Psychiatry Research, 2016, 244, 19-23.	3.3	57
5	Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. Journal of Psychiatric Research, 2015, 61, 64-72.	3.1	50
6	Changes in serum TNF-α, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge. Comprehensive Psychiatry, 2019, 90, 82-87.	3.1	49
7	The profile of cognitive impairments in chronic ketamine users. Psychiatry Research, 2018, 266, 124-131.	3.3	44
8	A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. Journal of Affective Disorders, 2018, 227, 372-378.	4.1	35
9	Chronic compression of mouse dorsal root ganglion alters voltage-gated sodium and potassium currents in medium-sized dorsal root ganglion neurons. Journal of Neurophysiology, 2011, 106, 3067-3072.	1.8	32
10	Increased Na <sup>+</sup> and K <sup>+</sup> currents in small mouse dorsal root ganglion neurons after ganglion compression. Journal of Neurophysiology, 2011, 106, 211-218.	1.8	31
11	Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers. Drug and Alcohol Dependence, 2014, 142, 290-294.	3.2	30
12	Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling. Molecular Psychiatry, 2021, 26, 4702-4718.	7.9	30
13	Effect of CXCL12/CXCR4 signaling on neuropathic pain after chronic compression of dorsal root ganglion. Scientific Reports, 2017, 7, 5707.	3.3	27
14	Elevated serum levels of TNF-α, IL-6 and IL-18 in chronic schizophrenic patients. Schizophrenia Research, 2014, 159, 556-557.	2.0	18
15	Relationship of serum levels of TNF-α, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers. Schizophrenia Research, 2015, 169, 10-15.	2.0	13
16	GRIN2B Gene Polymorphism in Chronic Ketamine Users. American Journal on Addictions, 2020, 29, 105-110.	1.4	9
17	Elevated serum levels of TNFâ€Î±, ILâ€6, and ILâ€18 in chronic methamphetamine users. Human Psychopharmacology, 2022, 37, e2810.	1.5	9
18	Serum level of vascular endothelial growth factor decreased in chronic ketamine abusers. Drug and Alcohol Dependence, 2015, 152, 57-61.	3.2	8

Ni Fan

#	Article	IF	CITATIONS
19	Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls. Human Psychopharmacology, 2020, 35, e2738.	1.5	8
20	Retrospective assessment of factors associated with readmission in a large psychiatric hospital in Guangzhou, China. Shanghai Archives of Psychiatry, 2014, 26, 138-48.	0.7	8
21	Effects of treatment status and life quality on anxiety in MMT patients. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 9.	2.2	6
22	Cortical Thickness Changes in Chronic Ketamine Users. Frontiers in Psychiatry, 2021, 12, 645471.	2.6	6
23	Association Analysis of Neuronal Nitric Oxide Synthase 1 Gene Polymorphism With Psychopathological Symptoms in Chronic Ketamine Users. Frontiers in Psychiatry, 2020, 11, 580771.	2.6	5
24	Development of a checklist of short-term and long-term psychological symptoms associated with ketamine use. Shanghai Archives of Psychiatry, 2015, 27, 186-94.	0.7	5
25	Low serum level of epidermal growth factor in chronic ketamine users. Human Psychopharmacology, 2018, 33, e2656.	1.5	Ο